Core Viewpoint - Guangji Pharmaceutical's stock price has shown a slight increase, reflecting market activity and potential investor interest amid ongoing corporate governance issues [1] Company Overview - Guangji Pharmaceutical is primarily engaged in the research, development, production, and sales of pharmaceutical raw materials and formulations, covering various fields including vitamins and antibiotics [1] - The company is currently controlled by Changjiang Industrial Investment Group, a significant industrial investment platform in Hubei Province, which also holds stakes in multiple listed companies [1] Recent Developments - The company’s stock price is reported at 7.14 yuan, with a daily increase of 0.85%, reaching a high of 7.16 yuan and a low of 7.03 yuan during trading [1] - The total market capitalization of Guangji Pharmaceutical stands at 2.476 billion yuan, with a negative price-to-earnings ratio [1] - Recent news indicates that Xie Bin, a member of the Changjiang Industrial Investment Group's party committee, is under investigation for serious violations of discipline and law, which may impact investor sentiment [1] Financial Activity - On August 11, the net outflow of main funds for Guangji Pharmaceutical was 2.8192 million yuan, with a cumulative net outflow of 4.1344 million yuan over the past five days [1]